moxifloxacin has been researched along with Bacterial Skin Diseases in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (6.25) | 18.2507 |
| 2000's | 5 (31.25) | 29.6817 |
| 2010's | 10 (62.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hayashi, Y; Katayama, M; Suzuki, D; Takimoto, K; Wang, Q | 1 |
| Arvis, P; Bogner, JR; Esguerra-Alcalen, M; Heldner, S; Kutaiman, A | 1 |
| Stein, RA | 1 |
| Chen, F; Du, YQ; Lin, JM; Tu, WF; Wang, Y; Wen, JL; Zheng, N | 1 |
| Demir, C; Durmuş, G; Eren, N; Karagöz, A; Kılıç, S; Yeşilyurt, M | 1 |
| Khatami, A; Sparks, R | 1 |
| Chu, Y; Jiang, MY; Luo, YF; Qu, J; Qu, LY | 1 |
| Amábile-Cuevas, CF; Arvis, P; Bogner, JR; Cruz-Alcázar, J; Hernández-Oliva, G; Reimnitz, P; Vick-Fragoso, R | 1 |
| Bae, SM; Cheong, HJ; Choi, WS; Kim, MJ; Park, DW; Sohn, JW; Son, SW; Song, T; Yoon, YK | 1 |
| Daza, RM; Lucena, JL; Ramos, A; Roustan, G | 1 |
| Alder, J; Arvis, P; Dryden, M; Gyssens, IC; Hampel, B; Kujath, P; Nathwani, D; Reimnitz, P; Schaper, N | 1 |
| Iakovlev, VP; Polushkina, NR | 1 |
| Giordano, P; Herrington, J; Kowalsky, S; Pertel, P; Song, J | 1 |
| Citron, DM; Goldstein, EJ; Hudspeth, M; Hunt Gerardo, S; Merriam, CV | 1 |
| Parish, LC; Routh, HB; Witkowski, JA | 1 |
| Blondeau, JM | 1 |
5 review(s) available for moxifloxacin and Bacterial Skin Diseases
| Article | Year |
|---|---|
Clinical efficacy of piperacillin/tazobactam in the treatment of complicated skin and soft tissue infections.
Topics: Anti-Bacterial Agents; Drug Therapy, Combination; Fluoroquinolones; Humans; Moxifloxacin; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Randomized Controlled Trials as Topic; Skin Diseases, Bacterial; Soft Tissue Infections; Treatment Outcome | 2017 |
Sequential intravenous/oral moxifloxacin monotherapy for complicated skin and skin structure infections: a meta-analysis of randomised controlled trials.
Topics: Administration, Oral; Anti-Bacterial Agents; Aza Compounds; Drug Therapy, Combination; Fluoroquinolones; Humans; Infusions, Intravenous; Middle Aged; Moxifloxacin; Quinolines; Randomized Controlled Trials as Topic; Skin Diseases, Bacterial; Treatment Outcome | 2013 |
A Meta-analysis of Sequential Intravenous/Oral Moxifloxacin Monotherapy for Treatment of Skin and Skin Structure Infections.
Topics: Administration, Intravenous; Administration, Oral; Anti-Bacterial Agents; Fluoroquinolones; Humans; Moxifloxacin; Skin Diseases, Bacterial | 2015 |
[Moxifloxacin: results of clinical use].
Topics: Anti-Infective Agents; Aza Compounds; Bronchitis, Chronic; Clinical Trials as Topic; Fluoroquinolones; Humans; Moxifloxacin; Pneumonia; Quinolines; Respiratory Tract Infections; Sinusitis; Skin Diseases, Bacterial; Treatment Outcome | 2002 |
The role of fluoroquinolones in skin and skin structure infections.
Topics: Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Clinical Trials as Topic; Drug Resistance, Microbial; Enterococcus; Fluoroquinolones; Gram-Negative Bacteria; Humans; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines; Skin Diseases, Bacterial; Staphylococcus aureus; Streptococcus | 2002 |
3 trial(s) available for moxifloxacin and Bacterial Skin Diseases
| Article | Year |
|---|---|
Efficacy and safety of sequential intravenous/oral moxifloxacin vs intravenous/oral amoxicillin/clavulanate for complicated skin and skin structure infections.
Topics: Administration, Oral; Adult; Aged; Amoxicillin; Aza Compounds; Clavulanic Acid; Female; Fluoroquinolones; Humans; Injections, Intravenous; Male; Middle Aged; Moxifloxacin; Prospective Studies; Quinolines; Skin Diseases, Bacterial; Treatment Outcome | 2009 |
A randomized trial of the efficacy and safety of sequential intravenous/oral moxifloxacin monotherapy versus intravenous piperacillin/tazobactam followed by oral amoxicillin/clavulanate for complicated skin and skin structure infections.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Aza Compounds; Double-Blind Method; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Male; Middle Aged; Moxifloxacin; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Quinolines; Skin; Skin Diseases, Bacterial | 2011 |
Sequential intravenous/oral moxifloxacin versus intravenous piperacillin-tazobactam followed by oral amoxicillin-clavulanate for the treatment of complicated skin and skin structure infection.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Aza Compounds; Double-Blind Method; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Tolerance; Female; Fluoroquinolones; Humans; Injections, Intravenous; Male; Middle Aged; Moxifloxacin; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Quinolines; Safety; Skin Diseases, Bacterial | 2005 |
8 other study(ies) available for moxifloxacin and Bacterial Skin Diseases
| Article | Year |
|---|---|
Moxifloxacin in complicated skin and skin structure infections (cSSSIs): A prospective, international, non-interventional, observational study.
Topics: Abscess; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Aza Compounds; Bites and Stings; Cellulitis; Cohort Studies; Debridement; Diabetic Foot; Drainage; Erysipelas; Female; Fluoroquinolones; Humans; Male; Middle Aged; Moxifloxacin; Prospective Studies; Quinolines; Skin Diseases, Bacterial; Skin Ulcer; Surgical Wound Infection; Treatment Outcome; Young Adult | 2013 |
Switch and gain - sequential moxifloxacin monotherapy.
Topics: Anti-Bacterial Agents; Aza Compounds; Fluoroquinolones; Humans; Moxifloxacin; Quinolines; Skin Diseases, Bacterial | 2013 |
[A severe cutaneous anthrax case complicated with sepsis in Bursa, Turkey].
Topics: Animals; Anthrax; Anti-Bacterial Agents; Aza Compounds; Bacillus anthracis; Debridement; Fluoroquinolones; Humans; Male; Middle Aged; Moxifloxacin; Penicillin G; Quinolines; Sepsis; Sheep; Skin Diseases, Bacterial; Turkey; Wounds and Injuries; Zoonoses | 2013 |
Mycobacterium fortuitum Complex Skin Infection in a Healthy Adolescent.
Topics: Adolescent; Anti-Bacterial Agents; Australia; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium fortuitum; Mycobacterium Infections, Nontuberculous; Skin Diseases, Bacterial; Trimethoprim, Sulfamethoxazole Drug Combination | 2014 |
Clarithromycin and amikacin vs. clarithromycin and moxifloxacin for the treatment of post-acupuncture cutaneous infections due to Mycobacterium abscessus: a prospective observational study.
Topics: Acupuncture Therapy; Amikacin; Anti-Bacterial Agents; Aza Compounds; Clarithromycin; Disease Outbreaks; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Korea; Male; Middle Aged; Moxifloxacin; Mycobacterium; Mycobacterium Infections; Prospective Studies; Quinolines; Skin Diseases, Bacterial; Time Factors; Treatment Outcome | 2011 |
[Development of subcutaneous nodules after mesotherapy].
Topics: Abscess; Adult; Anti-Bacterial Agents; Aza Compounds; Clarithromycin; Cutaneous Fistula; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Mesotherapy; Moxifloxacin; Mycobacterium chelonae; Mycobacterium Infections, Nontuberculous; Quinolines; Skin Diseases, Bacterial; Staining and Labeling; Subcutaneous Tissue | 2011 |
In vitro activity of Bay 12-8039, a new 8-methoxyquinolone, compared to the activities of 11 other oral antimicrobial agents against 390 aerobic and anaerobic bacteria isolated from human and animal bite wound skin and soft tissue infections in humans.
Topics: Administration, Oral; Anti-Infective Agents; Aza Compounds; Bacteria, Aerobic; Bacteria, Anaerobic; Bites and Stings; Bites, Human; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Moxifloxacin; Quinolines; Quinolones; Skin Diseases, Bacterial; Soft Tissue Infections; Wound Infection | 1997 |
Moxifloxacin (Avelox) for the treatment of bacterial skin infections.
Topics: Anti-Infective Agents; Aza Compounds; Fluoroquinolones; Humans; Moxifloxacin; Quinolines; Skin Diseases, Bacterial | 2001 |